Overview

Assessment of a Weight Management Program for Weight Gain in Patients With Schizophrenia

Status:
Completed
Trial end date:
2003-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to develop the weight management program, which is combined with healthy diet, proper physical exercise, and behavior modification, related to patient's quality of life. The patients groups are in routine practice with 5-20 mg olanzapine. The study results may be utilized for patients who have gained weight on olanzapine and also other antipsychotic drugs.
Phase:
Phase 4
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Olanzapine